GLP‐1 receptor agonists such as semaglutide and liraglutide, as well as combination agents like tirzepatide (which adds glucose‐dependent insulinotropic polypeptide receptor agonism)—all hereafter referred to as GLP‐1s for brevity—are effective new agents for obesity treatment which demonstrate weight reduction, weight maintenance, and reduced morbidity and mortality. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.